Bellone, Stefania <br/><br/>
Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  07 2018 
 - 3282-3291 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-17-1805  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Agents, Immunological--administration & dosage<br/>B7-H1 Antigen--genetics<br/>Biomarkers, Tumor<br/>Biopsy<br/>Computational Biology<br/>Drug Resistance, Neoplasm<br/>Female<br/>Gene Rearrangement<br/>HLA Antigens--immunology<br/>Humans<br/>Molecular Targeted Therapy<br/>Mutation<br/>Ovarian Neoplasms--diagnosis<br/>Positron Emission Tomography Computed Tomography<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Receptors, Cell Surface--genetics<br/>Retreatment<br/>T-Lymphocytes--drug effects<br/>Treatment Outcome<br/>Exome Sequencing